What Makes CSL Limited Sponsored ADR (CSLLY) a Good Fit for 'Trend Investing'Zacks Investment Research • 01/18/23
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus TherapeuticsPRNewsWire • 12/12/22
Ferinject® approved in Chinafor the treatment of iron deficiency in adult patientsBusiness Wire • 11/28/22
U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia BPRNewsWire • 11/22/22
Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022PRNewsWire • 11/02/22
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine TechnologyPRNewsWire • 11/01/22
Approval of extension of exemptions from SIX disclosure and publicity obligationsBusiness Wire • 10/20/22
CSL Plasma Expands in California with New Donation Centers to Collect Life-Saving PlasmaPRNewsWire • 10/11/22
CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic VaccinePRNewsWire • 10/06/22
CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine CandidatesPRNewsWire • 10/05/22
New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination RatesPRNewsWire • 09/26/22
New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health SystemsPRNewsWire • 09/26/22
CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XIPRNewsWire • 09/13/22